Casey Maguire, PhD, on Potential Advantages of Encapsulated AAVs
The associate professor and associate investigator of neurology at Harvard Medical School discussed research confirming proof-of-concept with EV-AAVs.
“We focused on the capsids inside the lumen and found that we could actually achieve transduction with them. So those are functional. It's been a long question that we actually were able to address. We're really happy about that. [Before now] we didn’t actually know, if we got more of that capsid packaged inside the vesicles, will that make a better gene delivery product? And that evidence suggests that yes, that would be a good strategy.”
Associated adeno-associated virus (AAV) vectors face challenges with safety and delivery of gene therapies. Combining AAV technology with viral-like particles (VLPs) may yield a product more efficacious than VLPs alone and safer than AAVs alone.
Casey Maguire, PhD, associate professor of neurology, Harvard Medical School, and associate investigator, Massachusetts General Hospital, presented research on EV-AAVs from his lab at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland.
CGTLive® spoke with Maguire to learn more about EV-AAVs and research ongoing with them. Maguire discussed his startup company revolving around EV-AAVs, Sphere Gene Therapeutics, and some collaborative research that may point to the best uses of this technology, including showing benefits in liver-targeted therapies compared to traditional AAVs. He also discussed looking deeper into intraluminal AAV packing with the EV-AAVs and confirming the efficacy of the encapsulated AAVs.
Click here to read more coverage of the 2024 ASGCT Annual Meeting.
